Education
About Us
Working with TipRanks
Follow Us
Axsome Therapeutics Inc (AXSM)
NASDAQ:AXSM
AXSM Stock Chart & Stats
$134.99
-$0.23(-0.27%)
At close: 4:00 PM EST
$134.99
-$0.23(-0.27%)
Day’s Range― - ―
52-Week Range$75.56 - $139.13
Previous CloseN/A
Volume140.83K
Average Volume (3M)448.60K
Market Cap
$6.74B
Enterprise Value$5.08B
Total Cash (Recent Filing)$303.02M
Total Debt (Recent Filing)$215.29M
Price to Earnings (P/E)―
Beta0.90
Next Earnings
Nov 03, 2025EPS Estimate
-0.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding49,901,485
10 Day Avg. Volume466,272
30 Day Avg. Volume448,597
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue10.27
Enterprise Value/Gross Profit11.22
Enterprise Value/Ebitda-22.60
Forecast
1Y Price Target
$172.36Price Target Upside27.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
Bulls Say, Bears Say
Bulls Say
Drug PerformanceSymbravo, AXSM's new migraine drug, showed a significant increase in prescriptions with a 55% rise in total prescriptions and a 48% rise in new prescriptions week-over-week.
Financial OutlookAxsome had $303 million in cash, which could fund the company into cash flow positivity given significant year-over-year top-line expansion and net loss contraction.
Sales Force ExpansionAxsome completed a sales force expansion for Auvelity, adding 40 reps to the sales force, which is expected to drive TRx growth.
Bears Say
Prescription TrendsSymbravo experienced a week-over-week decrease in both TRx and NRx figures after previously high growth.
Axsome Therapeutics News
AXSM FAQ
What was Axsome Therapeutics Inc’s price range in the past 12 months?
Axsome Therapeutics Inc lowest stock price was $75.56 and its highest was $139.13 in the past 12 months.
What is Axsome Therapeutics Inc’s market cap?
Axsome Therapeutics Inc’s market cap is $6.74B.
When is Axsome Therapeutics Inc’s upcoming earnings report date?
Axsome Therapeutics Inc’s upcoming earnings report date is Nov 03, 2025 which is today.
How were Axsome Therapeutics Inc’s earnings last quarter?
Currently, no data Available
Is Axsome Therapeutics Inc overvalued?
According to Wall Street analysts Axsome Therapeutics Inc’s price is currently Undervalued.
Does Axsome Therapeutics Inc pay dividends?
Axsome Therapeutics Inc does not currently pay dividends.
What is Axsome Therapeutics Inc’s EPS estimate?
Axsome Therapeutics Inc’s EPS estimate is -0.86.
How many shares outstanding does Axsome Therapeutics Inc have?
Axsome Therapeutics Inc has 49,901,485 shares outstanding.
What happened to Axsome Therapeutics Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Axsome Therapeutics Inc?
Currently, no hedge funds are holding shares in AXSM
Axsome Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$172.36 (27.68% Upside)
$172.36 (27.68% Upside)
Blogger Sentiment
Bullish
AXSM Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 86.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $200.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
51.62%
12-Months-Change
Fundamentals
Return on Equity
-280.68%
Trailing 12-Months
Asset Growth
16.70%
Trailing 12-Months
Company Description
Axsome Therapeutics Inc
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
AXSM Company Deck
AXSM Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with significant revenue growth and successful product launches. However, the substantial net loss and challenges in market access for SYMBRAVO present areas for concern.View all AXSM earnings summariesAXSM Stock 12 Month Forecast
Average Price Target
$172.36
▲(27.68% Upside)
Technical Analysis
Cytokinetics
―
Rhythm Pharmaceuticals
―
Legend Biotech
―
Avidity Biosciences
―
Nuvalent
―
Ownership Overview
15.86% Insiders
21.18% Mutual Funds
0.72% Other Institutional Investors
49.92% Public Companies and Individual Investors